參考文獻 |
[1] Clemens B, et al., “How valid is single nucleotide polymorphism (SNP) diagnosis for the individual risk assessment of breast cancer?” Gynecological Endocrinology, 2007
[2] Dent R, Clemons M., “Trastuzumab after primary treatment for early stage HER2-positive breast cancer reduces recurrence.” Cancer Treat Rev. Apr;32(2):144-8, 2006
[3] Norman SA, Potashnik SL, et al., “Modifiable risk factors for breast cancer recurrence: what can we tell survivors?” J Womens Health (Larchmt). Mar;16(2):177-90. Review, 2007
[4] Pandey R, Guru RK, Mount DW., “Pathway Miner: extracting gene association networks from molecular pathways for predicting the biological significance of gene expression microarray data.” Bioinformatics. Sep 1;20(13):2156-8. Epub 2004 May 14, 2004
[5] Hee-Joon Chung, Chan Hee Park, et al., “ArrayXPath II: mapping and visualizing microarray gene-expression data with biomedical ontologies and integrated biological pathway resources using Scalable Vector Graphics.” Nucleic Acids Research, Vol. 33, Web Server issue W621–W626, 2005
[6] Kanehisa M, Goto S, Hattori M, et al., “From genomics to chemical genomics: new developments in KEGG..” Nucleic Acids Res. Jan 1;34(Database issue):D354-7, 2006
[7] Edgar R, Barrett T., “NCBI GEO standards and services for microarray data.” Nat Biotechnol. Dec;24(12):1471-2. No abstract available, 2006
[8] Regidor PA, Callies R, Regidor M, Schindler AE., “Expression of the cell adhesion molecules ICAM-1 and VCAM-1 in the cytosol of breast cancer tissue, benign breast tissue and corresponding sera.” Eur J Gynaecol Oncol.; 19(4):377-83, 1998
[9] Varker KA, et al., “Impaired natural killer cell lysis in breast cancer patients with high levels of psychological stress is associated with altered expression of killer immunoglobin-like receptors.” J Surg Res. May 1;139(1):36-44. Epub 2007 Feb 9, 2007
[10] Vazquez-Martin A, Colomer R, Menendez JA., “Protein array technology to detect HER2 (erbB-2)-induced 'cytokine signature' in breast cancer.” Eur J Cancer. 2007 May;43(7):1117-24. Epub, 2007
[11] Galliher AJ, Schiemann WP., “Src phosphorylates Tyr284 in TGF-beta type II receptor and regulates TGF-beta stimulation of p38 MAPK during breast cancer cell proliferation and invasion.” Cancer Res. Apr 15;67(8):3752-8, 2007
[12] Cowell JK, Hawthorn L., “The application of microarray technology to the analysis of the cancer genome.” Curr Mol Med. Feb;7(1):103-20. Review, 2007
[13] Liang P, Pardee AB., “Analysing differential gene expression in cancer.” Nat Rev Cancer. Nov;3(11):869-76. Review. No abstract available, 2003
[14] Frolov AE, Godwin AK, Favorova OO., “Differential gene expression analysis by DNA microarrays technology and its application in molecular oncology.” Mol Biol (Mosk). Jul-Aug;37(4):573-84. Review. Russian, 2003
[15] Gusnanto A, Calza S, Pawitan Y., “Identification of differentially expressed genes and false discovery rate in microarray studies.” Curr Opin Lipidol. Apr;18(2):187-93. Review, 2007
[16] Norman SA, Potashnik SL, Galantino ML, De Michele AM, House L, Localio AR., “Modifiable risk factors for breast cancer recurrence: what can we tell survivors?” J Womens Health (Larchmt). Mar;16(2):177-90. Review, 2007
[17] Kreike B, Halfwerk H, Kristel P, Glas A, Peterse H, Bartelink H, van de Vijver MJ., “Gene expression profiles of primary breast carcinomas from patients at high risk for local recurrence after breast-conserving therapy.” Clin Cancer Res. Oct 1;12(19):5705-12, 2006
[18] Foekens JA, et al., “Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer.” J Clin Oncol. 2006 Apr 10;24(11):1665-71. Epub, 2006
[19] Hall P, et al., “Hormone-replacement therapy influences gene expression profiles and is associated with breast-cancer prognosis: a cohort study.” BMC Med. Jun 30;4:16, 2006
[20] Ivshina AV et al., “Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer.” Cancer Res. Nov 1;66(21):10292-301, 2006 |